Both SGLT2-i and valsartan/sacubitril reduce Na+ reabsorption in the proximal tubule and therefore stimulate TGF
Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts
"If you don't get good guidance, you're not going to see the optimal effects and then if you don't get good guidance when you lose access or want to adapt your dose, that can really worsen the rebound weight gain and all the negative aspects of coming off those medicines." Dr
[49] Sharretts, J., Galescu, O., Gomatam, S., Andraca-Carrera, E., Hampp, C., & Yanoff, L
This suggests that GLP-1 RA exposure itself may not be driving the increased risk, but rather factors related to the underlying indication for prescription (i.e., diabetes) may be contributory
Endocrinology (2015) 156:312236